Introduction
============

Primary neuroendocrine cancer of the breast (NECB) is an extremely rare tumor. In 2003, the World Health Organization (WHO) recognized this category with three well-described subtypes: small cell, large cell, and carcinoid-like carcinoma.

Extrapulmonary small-cell neuroendocrine carcinomas account for 2.5%--5% of all small-cell neuroendocrine carcinomas \[[@b1-cm-86-156]\].

Neuroendocrine small cell carcinoma with features indistinguishable from pulmonary small cell carcinoma can occur in a variety of extrapulmonary sites. These tumors have been reported in the breast, larynx, trachea, stomach, small intestine, bladder prostate, cervix, ovary and many other organs and tissues \[[@b2-cm-86-156]--[@b5-cm-86-156]\].

Contrary to pulmonary small cell carcinomas, extra pulmonary tumors of this type are very uncommon. Reports also suggest that clinical course of extrapulmonary SCNC is as aggressive as its pulmonary counterpart \[[@b6-cm-86-156],[@b7-cm-86-156]\].

Since its first description by Wade et al. in 1983, we were able to find only 35 recorded cases in literature ([Table I](#tI-cm-86-156){ref-type="table"}) \[[@b8-cm-86-156]--[@b27-cm-86-156]\].

Case report
===========

A 53 year old female patient was admitted to the Cluj-Napoca Institute of Oncology with a palpable mass in her right breast for specialty treatment.

On examination the right breast showed a mass of about 12 cm in diameter in the lower-inner and intern quadrants. She had a 3 cm ipsilateral axillary lymphadenopathy. The left breast examination and other clinical examinations were within normal limits.

Mammography and echography revealed suspicious characteristics in the nodule ([Figures 1](#f1-cm-86-156){ref-type="fig"}&[2](#f2-cm-86-156){ref-type="fig"}).

A core biopsy revealed a solid small-cell neuroendocrine carcinoma, G III with negative estrogen and progesterone receptors. IHC: CK AE1/AE3 pozitive, CD56 pozitive, TTF1 negative, chromogranin and synaptophysin negative.

CT/MRI scans of the lung, abdomen and bone were normal.

Confirming the breast as an origin of neuroendocrine tumor represents a challenge. The diagnosis is mainly dependent on the exclusion of other extra-mammary organs based on clinical, radiological, pathological and IHC data.

In conclusion Small-cell neuroendocrine breast cancer - T4bN2M0.

The patient underwent neo-adjuvant chemotherapy, 4 cycles: Farmorubicin 100 mg/mp DT = 165 mg; Ciclofosfamida 600 mg/mp DT = 980 mg and 4 cycles: Taxotere 75 mg/mp DT = 125 mg.

Partial result was achieved after neo-adjuvant therapy, the tumor being reduced to 5 cm in diameter. Again the CT/MRI scans were normal.

Subsequently the patient underwent a right radical mastectomy with axillary lymph node resection. Macroscopically, the tumor was 4--5 cm in maximum diameter. Widespread vascular invasion was present; 21 of 30 lymph nodes were metastatic.

It was decided by a multi disciplinary team that adjuvant radiotherapy was needed.

Eight months after diagnosis and one month after MRM the patient presented signs of local recurrence in the form of permeation nodules. After skin biopsy the diagnosis was confirmed.

After other investigations, CT, Rx lung and liver metastasis were discovered.

Radiotherapy was started along with hyperthermia and a new chemotherapy regime was considered.

The study was performed with the patient's consent and the approval of the hospital's ethic committee.

Discussion
==========

Small cell neuroendocrine breast cancer is generally characterized by early dissemination and a rapid, aggressive clinical course. However, the biological behaviour of mammary SmCC is still uncertain because this type of breast tumor is less frequently encountered. There are several reports, which consist largely of case reports, and these reported patients showed a relatively poor prognosis with a more advanced stage at diagnosis \[[@b28-cm-86-156]--[@b30-cm-86-156]\]. The stage of the disease at the time of diagnosis is an important determining factor of the prognosis \[[@b31-cm-86-156]\].

Conclusion
==========

Treatment for the SmCC of the breast has not yet been established, and a consensus has yet to be reached. It is clear that more studies are needed in order to achieve an effective treatment. Unfortunately cases are very rare and their evolution very poor, making it difficult to come up with a proper treatment.
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###### 

Published case reports of neuroendocrine carcinoma of the breast.

  No.   First author \[Ref\]             Year       Age/Sex    TNM            Size (mm)   IS   Treatment           Follow-up (months)   Outcome
  ----- -------------------------------- ---------- ---------- -------------- ----------- ---- ------------------- -------------------- ---------
  1     Wade \[[@b8-cm-86-156]\]         1983       52/F       T4N1M1         100         −    MRM/CT              9                    DOD
  2     Jundt \[[@b9-cm-86-156]\]        1984       52/M       T~x~N1M~x~     NS          −    CT/RT               14                   DOD
  3     Papotti \[[@b10-cm-86-156]\]     1992       64/F       T1N0M0         20          \+   SRM                 44                   NED
  4                                      1992       41/F       T2N1M0         35          \+   SRM/RT              15                   DOD
  5                                      1992       50/F       T2N1M0         30          \+   SRM                 14                   DOD
  6                                      1992       69/F       T3N1M0         50          \+   MRM                 9                    DUD
  7     Francois \[[@b11-cm-86-156]\]    1995       68/F       T2N0M0         40          −    MRM/RT              21                   DUD
  8     Chua \[[@b12-cm-86-156]\]        1997       45/F       T2N0M~X~       45          NS   TR                  NS                   NS
  9     Fukunaga \[[@b13-cm-86-156]\]    1998       56/F       T4N1M~X~       100         \+   SRM                 48                   NED
  10    Yamasaki \[[@b14-cm-86-156]\]    2000       41/F       T2N0M0         45          \+   MRM/CT              16                   NED
  11    Shin \[[@b15-cm-86-156]\]        2000       43/F       T1N~X~M0       13          \*   BCS/RT              30                   NED
  12                                     2000       44/F       T1N0M0         20          \*   BCS/CT/RT           27                   NED
  13                                     2000       46/F       T2N1M0         34          \*   MRM/CT              11                   AWD
  14                                     2000       50/F       T2N1M0         22          \*   BCS/CT              35                   NED
  15                                     2000       51/F       T1N0M0         15          \*   BCS/RT              25                   NED
  16                                     2000       57/F       T2N0M0         25          \*   MRM/CT              10                   NED
  17                                     2000       62/F       T2N0M0         50          \*   NAC/MRA/CT          32                   AWD
  18                                     2000       64/F       T1N0M0         18          \*   TR/CT               10                   NED
  19                                     2000       70/F       T2N1M0         40          \*   BCS                 3                    NED
  20    Samli \[[@b16-cm-86-156]\]       2000       60/F       T4N1M0         80          −    NAC/MRM/CT/RT       6                    AWD
  21    Salmo \[[@b17-cm-86-156]\]       2001       46/F       T2N0M0         40          \+   TR/CT/RT            9                    NED
  22    Hoang \[[@b18-cm-86-156]\]       2001       41/F       T~X~N~X~M~X~   145         \+   NS                  NS                   NS
  23                                     2001       51/F       T~X~N~X~M~X~   80          \+   NS                  NS                   NS
  24    Bergman \[[@b19-cm-86-156]\]     2004       61/F       T2N1M0         25          \+   MRM                 NS                   NS
  25    Sridhar \[[@b20-cm-86-156]\]     2004       58/F       T1N1M0         20          −    BCS/CT/RT           18                   NED
  26    Bigotti \[[@b21-cm-86-156]\]     2004       56/F       T3N1M0         180         \+   NAC/SRM/CT          14                   DOD
  27    Jochems \[[@b22-cm-86-156]\]     2004       71/F       T2N0M0         30          −    MRM                 12                   NED
  28    Yamamoto \[[@b23-cm-86-156]\]    2004       53/F       T3N2M0         65          NS   NS                  34                   NED
  29                                     2004       75/F       T2N1M0         25          NS   NS                  43                   NED
  30    Adegbola \[[@b24-cm-86-156]\]    2005       46/F       T1N0M0         10          −    TR/CT/RT            48                   NED
  31                                     2005       60/F       T1N0M0         17          \+   TR/CT/RT            20                   DOD
  32                                     2005       61/F       T1N1M0         17          −    TR/CT/RT            6                    AWD
  33    Stein \[[@b25-cm-86-156]\]       2005       54/F       T1N1M0         20          NS   NAC/MRM/RT          24                   NED
  34    Salman \[[@b26-cm-86-156]\]      2006       NS/F       T2N~X~M0       50          \+   NAC/MRM             NS                   NS
  35    Kinoshita \[[@b27-cm-86-156]\]   2008       31/F       T3N1M0         60          \+   NAC/MRM/CT          6                    DOD
        **Present case**                 **2012**   **53/F**   **T4N3M1**     **110**     −    **NAC/MRM/RT-CT**   **9**                **AWD**
